GleamWall
中文EN

VISK Viskase Holdings, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 727510 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY59.0%
TTM EPS YoY182.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-21.6%
ROA-8.2%
ROIC (approx.)-4.0%
Asset turnover—

Leverage & solvency

Liabilities / assets58.4%
Debt / equity1.52x
Current ratio1.07x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.44x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$26,000
Operating income-$5.31M-$1.33M
Pretax income-$3.39M$1.12M
Income tax$19,000$347,000
Net income-$3.41M$778,000
EPS (basic)-0.07-0.01
EPS (diluted)-0.07-0.01
Weighted avg. shares (diluted)74.22M74.22M
Balance sheet
Cash & equivalents$9.22M$5.70M
Receivables$60.18M—
Inventory$96.75M—
Current assets$208.65M$47.15M
PP&E, net$141.30M—
Goodwill$3.13M—
Intangibles$13.40M—
Total assets$402.14M$47.17M
Current liabilities$214.52M$1.68M
Short-term debt$141.77M—
Long-term debt$141.77M—
Total debt$283.55M—
Total liabilities$257.78M-$122.82M
Shareholders' equity$145.84M$3.01M
Net debt$274.33M—
Shares outstanding6.61M74.21M
Cash flow statement
Operating cash flow-$3.01M$1.12M
Financing cash flow-$1.27M-$1.27M
Stock-based compensation—$0
Dividends paid$1.27M$1.27M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.